13.3 Biologics & Immunologic Therapies
Key Takeaways
- Monoclonal antibodies and other biologics are protein-based therapies that often require controlled infusion rates, observation for hypersensitivity, and product-specific filters, diluents, and light/temperature handling.
- IVIG needs careful rate titration (start low, advance as tolerated), hydration/renal risk awareness, and vigilance for aseptic meningitis, thrombosis, and renal complications—especially in high-risk patients.
- Colony-stimulating factors (e.g., G-CSF/GM-CSF class agents) support neutrophil recovery; know route (often subcutaneous for many outpatient regimens), timing relative to chemotherapy, and bone pain as a common effect.
- Hypersensitivity and infusion reactions range from mild flushing to anaphylaxis; use ordered premedication, graded rate increases, emergency medications at the chairside, and awareness of biphasic anaphylaxis after apparent recovery.
- Specialty pharmacy and home infusion models require cold-chain integrity, first-dose policies, patient education, and clear escalation pathways for delayed reactions outside the hospital.
Biologics and immunologic infusions on the CRNI blueprint
Domain 3D Biologic and Immunologic Therapy spans monoclonal antibodies (mAbs), immune globulins (IVIG/SCIG concepts), colony-stimulating factors, and related protein therapeutics used in immunology, hematology, oncology-adjacent care, and autoimmune disease. These agents are not ordinary crystalloid drips: they are immunologically active, often expensive specialty products with strict handling rules and a meaningful risk of infusion reactions.
Quick Answer: Biologics need product-specific rates, filters, diluents, and reaction monitoring. IVIG: titrate rate; watch aseptic meningitis, renal injury, thrombosis. Know CSF supportive roles and common bone pain. Use premedication when ordered; prepare for anaphylaxis and biphasic recurrence. Home/specialty pharmacy care needs cold chain, education, and escalation plans.
Monoclonal antibodies: concepts for infusion nurses
Monoclonal antibodies are laboratory-produced antibodies that target specific antigens (receptors, cytokines, cell-surface markers). From a nursing operations view, they share patterns even when brand names differ:
| Theme | Why it matters at the chair |
|---|---|
| Protein load / immunogenicity | Body may treat the drug as foreign → infusion reactions, anti-drug antibodies, loss of efficacy over time |
| First-dose effect | Initial infusions often carry the highest reaction risk; longer observation may be required |
| Rate titration | Many protocols start slow and escalate only if tolerated |
| Premedication | Acetaminophen, antihistamines, and sometimes corticosteroids as ordered for higher-risk agents |
| Filter / diluent / light | Some products require in-line filters of a specific micron size; others prohibit filters—read the label |
| Do not shake | Agitation can denature proteins; gentle invert to mix |
| Compatibility | Dedicated line preferred; NS is common diluent but product-specific |
Examples you may see in practice include agents targeting TNF pathways, CD20, HER2, complement, or checkpoint pathways—exact rosters change with formularies. CRNI cares that you follow the product monograph and order set, not that you invent a universal rate for “all antibodies.”
Exam trap: Shaking a mAb vial vigorously “to dissolve faster,” or bolusing a first dose because the clinic is behind schedule.
Intravenous immune globulin (IVIG)
IVIG is pooled human immunoglobulin used for immunodeficiency, selected autoimmune/neurologic indications, and other specialty diagnoses. Administration is a core infusion skill.
Rate titration
- Start at a low rate and increase in steps only if the patient remains stable (exact steps are order- and product-specific).
- Higher rates increase risk of headache, flushing, chills, myalgias, blood pressure changes, and more serious events.
- Patients naïve to IVIG, those with prior reactions, or those with cardiac/renal risk may need slower schedules and longer observation.
- SCIG (subcutaneous immune globulin) is an alternate route for some patients—different nursing education (pump or push, local site reactions) but same product-class respect for immune adverse effects.
Major IVIG risks (high-yield)
| Risk | Clinical notes | Nursing actions |
|---|---|---|
| Infusion/hypersensitivity reactions | Range from mild flu-like symptoms to anaphylaxis (especially IgA-deficient patients with anti-IgA antibodies in classic teaching) | Stop or slow; emergency meds ready; report prior reactions |
| Aseptic meningitis | Severe headache, neck stiffness, photophobia days after infusion—CSF sterile | Take headaches seriously; hydrate; notify provider; not “just a migraine to ignore” |
| Renal complications | Acute kidney injury risk—historically higher with certain sucrose-stabilized products; risk rises with preexisting renal disease, dehydration, age | Hydrate as ordered; monitor urine output/creatinine; avoid concurrent nephrotoxins when possible |
| Thrombosis / thromboembolism | Arterial or venous clots—risk with high dose/rapid infusion, immobility, hyperviscosity, cardiovascular disease | Do not race the rate; mobility/VTE awareness; report chest pain, limb swelling, neuro changes |
| Hemolysis | Positive DAT/hemolysis themes with some products/doses | Report dark urine, falling hemoglobin, jaundice |
| Fluid overload | Large volume loads in cardiac patients | Assess volume status; slower rates; split dosing when ordered |
Premedication, adequate hydration, and not exceeding maximum rates are prevention pillars. Document lot numbers for traceability when reactions or product issues occur.
Colony-stimulating factors
Colony-stimulating factors (e.g., G-CSF such as filgrastim class agents; GM-CSF where used) stimulate marrow production of neutrophils (and related lineages depending on agent). Infusion/clinic nursing themes:
- Many outpatient regimens are subcutaneous rather than prolonged IV—verify route; do not assume IV.
- Timing relative to chemotherapy matters (often not same-day as certain chemo doses)—follow oncology orders exactly.
- Bone pain is a common adverse effect (marrow expansion); comfort measures and ordered analgesics help.
- Monitor CBC trends as ordered; report unexpected leukocytosis symptoms or splenic pain (rare splenomegaly/rupture teaching points with G-CSF).
- Biosimilars and pegylated long-acting forms change dosing frequency—check the specific product.
CSF therapy is supportive care that enables chemotherapy intensity; missed doses or wrong timing can leave patients neutropenic longer or, conversely, stimulate marrow at the wrong phase of treatment.
Hypersensitivity and infusion reactions
Spectrum
| Severity | Examples | Response themes |
|---|---|---|
| Mild | Flushing, isolated pruritus, low-grade fever, mild nausea | Slow or pause; assess; antihistamine/antipyretic as ordered; possible cautious restart at lower rate |
| Moderate | Urticaria, rigors, significant BP change, chest tightness without full anaphylaxis | Stop; treat; provider decision on rechallenge with desensitization protocols if essential |
| Severe / anaphylaxis | Bronchospasm, stridor, angioedema, hypotension, collapse | Stop drug; epinephrine IM per protocol; airway support; call emergency response; do not leave patient alone |
Differentiate cytokine-release / infusion reactions common with some biologics from classic IgE anaphylaxis—both can look dramatic; treatment still begins with stop the drug and support ABCs. Desensitization is a specialist procedure, not bedside improvisation.
Premedication and preparedness
- Give ordered premeds on time before start (too early or too late reduces benefit).
- Have emergency medications and equipment available before spiking high-risk first doses.
- Use pulse oximetry and frequent vitals during escalation phases.
- Educate patients to report throat tightness, hives, or impending doom early—not after the bag is empty.
Biphasic anaphylaxis awareness
Biphasic anaphylaxis is recurrence of significant allergic symptoms after apparent resolution, without re-exposure, hours later (classically within about 1–72 hours, often within the first 8–12 hours in teaching ranges). Implications:
- Observation periods after treated anaphylaxis exist for a reason—do not rush discharge the moment vitals normalize.
- Provide clear return precautions: recurrent wheeze, swelling, syncope → emergency care.
- Document epinephrine use and response; ensure auto-injector education if going home after clinic anaphylaxis care per provider plan.
Exam trap: Declaring a patient “fine” 10 minutes after epinephrine and sending them home without observation guidance when biphasic risk remains.
Specialty pharmacy and home infusion
Many biologics ship from specialty pharmacies with white-glove delivery:
| Logistics element | Nursing/patient safety angle |
|---|---|
| Cold chain | Refrigerate as labeled; do not freeze; do not leave on a sunny porch |
| Beyond-use dating | Compounded syringes/bags expire—do not extend dates |
| First-dose policy | High-risk agents may require monitored facility for dose 1 |
| Self-administration training | SC biologics: site rotation, sharps disposal, missed-dose rules |
| Pump and IVIG home programs | Similar to OPAT—access care, rate plans, 24/7 on-call |
| Insurance/PA delays | Clinical deterioration if therapy gaps—escalate care coordination |
| Waste and spills | Some agents have hazardous handling overlays; follow SDS/policy |
Home patients need written parameters: when headache after IVIG is expected vs emergency, how to store drug during power outages, and who to call for pump alarms. Infusion nurses often perform home visits or teach clinic self-injection—competency check-offs prevent silent nonadherence.
Integrated scenarios
Scenario A — IVIG headache with stiff neck day 2: Consider aseptic meningitis; notify provider; do not dismiss as ordinary post-infusion headache without evaluation.
Scenario B — First mAb dose wheezing: Stop infusion, call for help, epinephrine if anaphylaxis criteria met, oxygen, remain with patient; document and report to specialty pharmacy/manufacturer as required.
Scenario C — Home biologic warm to touch after shipping delay: Do not inject; contact specialty pharmacy for product viability guidance.
Scenario D — G-CSF bone pain: Expected common effect; treat comfort as ordered; still rule out other acute pain causes if atypical (e.g., LUQ concerning for rare splenic issues).
High-yield exam traps (biologics & immunologic)
- Racing IVIG to “get the patient home” despite thrombosis/renal risk factors
- Ignoring severe headache/photophobia after IVIG
- Skipping premedication timing or emergency drug readiness on first doses
- Shaking protein products or using the wrong filter
- Missing biphasic anaphylaxis discharge teaching/observation needs
- Giving CSF on the wrong schedule relative to chemotherapy
- Using a heat-damaged specialty pharmacy shipment
- Treating all infusion reactions as mild anxiety without stopping the drug
Which IVIG administration principle is most accurate?
A patient treated for anaphylaxis during a biologic infusion improves after epinephrine but is ready for immediate discharge 15 minutes later with no observation plan. What safety concern should guide nursing advocacy?
Which statement best reflects colony-stimulating factor (e.g., G-CSF) therapy concepts for infusion nurses?
Before initiating a first-dose monoclonal antibody infusion, which preparation bundle is most appropriate?